Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
about
GATA-1 and Gfi-1B interplay to regulate Bcl-xL transcriptionUpdate on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinibPrecision medicine for cancer with next-generation functional diagnosticsGenetics of myeloproliferative neoplasmsImatinib in chronic myeloid leukemia: an overviewCurrent status of hematopoietic stem cell transplant in chronic myeloid leukemiaAclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiationGrowth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugateIdentification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemiasInhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cellsIcaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalingsMATE1 regulates cellular uptake and sensitivity to imatinib in CML patientsStrategies for modern biomarker and drug development in oncology.Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.Subdural hematomas during CML therapy with imatinib mesylate.Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.Hematologic toxicities of small molecule tyrosine kinase inhibitors.Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study.Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.Emerging drugs for chronic myeloid leukemia.A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.Imatinib: a breakthrough of targeted therapy in cancer.Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor.Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea.Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.Practical management of patients with chronic myeloid leukemia.Targeted treatment of chronic myeloid leukemia: role of imatinib.It's about time: lessons for solid tumors from chronic myelogenous leukemia therapyRole of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisitedPruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisImatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST).A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate.Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysisAnaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage.Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells
P2860
Q24683168-029E7F21-781C-47C4-BF10-D710BA895C0AQ26751285-5CABF75A-A547-4F5A-BECA-AB2D69E49F45Q26780232-9D665FF9-77A3-4771-B3E6-57618B849DDAQ26823651-BAE9E25F-63EA-4289-841A-9FD825400A88Q26865086-C5D5A951-32D8-4BB6-BD3E-0A62DFFE5D9EQ27010475-7698485B-58E9-44CA-8601-F6FFF4FA5330Q28397002-3B1E4556-B5ED-4477-8796-D448E165DF75Q28473957-DBDD4C26-D10F-4967-A321-1F1A8426F865Q28540799-1C6456DD-FDD4-4D67-BF91-F1274477B4C9Q28545195-7B5BC955-4776-48DF-BB2C-DCD4E3513389Q28741022-8F64CD70-C75E-4067-B571-EFB3302B21D9Q30313870-C7C903E2-5BC7-4349-80E4-1CDA2E733BA8Q30590270-D9271DEC-1586-4DC5-BC27-7DB15C369BE1Q33357697-0E26FEAC-DCD7-47AA-BB6D-562102D3A653Q33362624-77DF6140-B6D9-48A0-A05A-28DF522C4730Q33368010-0AF2773D-010A-42B3-934C-D36401D98DD5Q33384766-495D2CAD-7680-46B7-9BB9-C0C0C66A999FQ33396265-62E3B2B8-E2D4-41EA-BFC2-27802763F1C1Q33398183-B4977B64-D925-4358-AF7B-3EE3CA4E0D7CQ33398485-C102602D-B29D-4F74-A64A-018CA0897497Q33412429-30A4CDD5-09E1-4328-AB66-71DADEA84816Q33423255-F377C74E-6FF7-4601-910E-BDD592F7B84AQ33482818-EFB2FCFF-A339-4D09-B04A-68E72D604BA5Q33536762-5C34C963-2204-4B61-A783-0D7C1AB9220DQ33597519-59CAEA42-4A3D-4554-AB5D-70EF8BFE0EB4Q33747261-616144CA-21BB-4D3C-8D4E-DC4102D7F4A5Q33765281-C149622A-26A5-4C7C-B4F5-492726B69D32Q33828071-83948026-D9C6-4EEF-BD8B-98AB3964896EQ33844109-E659688A-B630-464F-9985-EC0A98E89626Q33849146-CC3D8233-2373-401E-B4EB-D75192E1D411Q33915973-787BC49A-9155-4305-BA8B-430169D90E5CQ33936071-3D2F4FB7-E96D-4114-9001-FC8ED853D7B9Q34065058-4BB6378E-F59B-43FD-9DDA-2D59C1714F37Q34272887-5A6897F3-7EE5-4203-9E5D-07C415168925Q34276167-9304DB92-286B-4E2D-B664-4C730A82BAADQ34316796-E4B0589A-9EF0-409B-8188-EBC5B8A615BEQ34443523-EED506D5-851E-4C15-912F-3590AC407762Q34445704-895A347F-6D18-449B-BC91-F71111906CDEQ34552993-D9966ED9-2A42-4325-AB4B-BADECF8F93D1Q34565011-296DA376-6A34-4292-A764-6BC6B8B1E09B
P2860
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Imatinib induces durable hemat ...... a: results of a phase 2 study.
@en
Imatinib induces durable hemat ...... a: results of a phase 2 study.
@nl
type
label
Imatinib induces durable hemat ...... a: results of a phase 2 study.
@en
Imatinib induces durable hemat ...... a: results of a phase 2 study.
@nl
prefLabel
Imatinib induces durable hemat ...... a: results of a phase 2 study.
@en
Imatinib induces durable hemat ...... a: results of a phase 2 study.
@nl
P2093
P50
P356
P1433
P1476
Imatinib induces durable hemat ...... a: results of a phase 2 study.
@en
P2093
Anne L Lennard
Charles A Schiffer
Charles L Sawyers
Francois Guilhot
Francois-Xavier Mahon
Insa Gathmann
John M Goldman
Michael W N Deininger
Moshe Talpaz
Renaud Capdeville
P304
P356
10.1182/BLOOD.V99.6.1928
P407
P50
P577
2002-03-01T00:00:00Z